Global Travel Vaccines Market Report and Forecast 2024-2032

Global Travel Vaccines Market Outlook 

The global travel vaccines market size attained a value of about USD 3.87 billion in 2023, driven by rising prevalence of infectious and travel-related diseases such as Japanese encephalitis, meningitis, diphtheria, and yellow fever. The market is further expected to grow at a CAGR of 10.7% during the forecast period of 2024-2032 to reach nearly USD 9.67 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

On the basis of the composition, the combination vaccines segment accounted for the majority of the global travel vaccines market share, as it protects the travellers against multiple diseases. Based on the disease, the hepatitis A segment dominated the industry in 2020. Regionally, North America held the most significant market share in 2020, on account of the presence of a large number of companies in the region who are introducing a superior range of travel vaccines.

Properties and Applications

Travel vaccines are immunization shots, which travellers get before visiting any region across the world. These vaccines build immunity against viral as well as microbial invasions while improving the overall health of the individual. In addition, the body responds to the vaccination by making antibodies and protecting it against a situation where there is an exposure to the disease. These immunizations must be taken at least 4 to 6 weeks before travelling as this gives enough time for the immunization to start working efficiently.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The major compositions of the global travel vaccines market are:

• Mono Vaccines
• Combination Vaccines

The industry can be broadly categorised on the basis of the diseases segment into:

• Hepatitis A 
• DPT
• Yellow Fever
• Typhoid
• Hepatitis B
• Measles and Mumps
• Rabies
• Meningococcal
• Varicella
• Japanese Encephalitis
• Others

The EMR report looks into the regional markets in the global travel vaccines market like North America, the Asia Pacific, Europe, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis

The rising prevalence of infectious and travel-related diseases, such as Japanese encephalitis, meningitis, diphtheria, and yellow fever, is one of the prime factors that are driving the growth of the industry. In addition to this, the rising globalization and reduced international airfares have led to an increase in international tourism. Consequently, travel vaccines have now become an important requirement in an international travellers’ list, with its market witnessing a significant growth globally. Several combination vaccines have also been introduced for travellers, which protect against more than one disease, thus, supporting the industry growth as they increasingly gain popularity. Additionally, governments across several countries are heavily investing in the promotion of the use of these vaccines. For instance, the Ministry of Health in the Kingdom of Saudi Arabia (KSA) requires that all travellers arriving for Hajj and Umrah from other countries must present a valid vaccination certificate. Other factors driving the demand for travel vaccines include increasing awareness levels, technological advancements, and increasing incidences of life-threatening infectious diseases.

Competitive Landscape

The report presents a detailed analysis of the following key players in the global travel vaccines market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• GlaxoSmithKline plc.
• Merck & Co., Inc 
• Sanofi
• Pfizer Inc.
• CSL Limited
• Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report